Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France

Neurology

Volumn 53, Issue 6, 1999, Pages 1197-1201

  Huillard D'Aignaux, J ^a   Costagliola, D ^b   Maccario, J ^b   De Villemeur, T Billette ^a   Brandel, J P ^a   Deslys, J P ^c   Hauw, J J ^a   Chaussain, J L ^d   Agid, Y ^a   Dormont, D ^c   Alperovitch A ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

^c DIF   (France)

^d HÔPITAL SAINT VINCENT DE PAUL   (France)

Author keywords

Creutzfeldt Jakob disease; Hormone; Iatrogenic disease; Incubation period; Models, statistical

Indexed keywords

HUMAN GROWTH HORMONE; PRION PROTEIN;

ARTICLE; CREUTZFELDT JAKOB DISEASE; FRANCE; HUMAN; IATROGENIC DISEASE; INCIDENCE; INCUBATION TIME; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; PRIORITY JOURNAL;

EID: 0000926966     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.6.1197     Document Type: Article

References (20)

1. Gadjusek DC, Zigas V. Degenerative disease of the central nervous system in New Guinea. N Engl J Med 1997;257:974-982.
2. de Silva R, Esmonde T. Iatrogenic transmission of Creutzfeldt-Jakob disease. CNS Drugs 1992;2:96-101.
3. Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996;347:921-925.
4. Collinge J, Sidle KCL, Meads J, Ironside JW, Hill AF. Molecular analysis of prion strain variation and the aetiology of "new variant" CJD. Nature 1996;383:685-690.
5. Bruce ME, Will RG, Ironside JW, et al. Transmission to mice indicates that "new variant" CJD is caused by the BSE agent. Nature 1997;389:498-501.
6. Cousens SN, Vynnycky E, Zeider M, Will RG, Smith PG. Predicting the CJD epidemic in humans. Nature 1997;385:197-200.
7. Brown P, Preece MA, Will RG. "Friendly fire" in medicine: hormones, homografts, and Creutzfeldt-Jakob disease. Lancet 1992;340:24-27.
8. Fradkin JE, Schonberger LB, Mills JL, et al. Creutzfeldt-Jakob disease in pituitary growth hormone recipients in the United States. JAMA 1991;265:880-884.
9. Job JC, Maillard F, Goujard J. Epidemiologic survey of patients treated with growth hormone in France in the period 1959-1990: preliminary results. Horm Res 1992;38:35-43.
10. Billette de Villemeur T, Deslys JP, Pradel A, et al. Creutzfeldt-Jakob disease from contaminated growth hormone extracts in France. Neurology 1996;47:690-695.
11. Huillard d'Aignaux J, Alpérovitch A, Maccario J. A statistical model to identify the contaminated lots implicated in iatrogenic transmission of Creutzfeldt-Jakob among French human growth hormone recipients. Am J Epidemiol 1998;147: 597-604.
12. Brookmeyer R, Goedert J. Censoring in an epidemic with an application to hemophilia-associated AIDS. Biometrics 1989; 45:325-335.
13. Medley GF, Anderson RM, Cox DR, Billard L. Incubation period of AIDS in patients infected via blood transfusion. Nature 1987;328:719-721.
14. Costagliola D, Mary JY, Brouard M, Laporte A, Valleron AJ. Incubation time for AIDS from French transfusion-associated cases. Nature 1989;338:768-769.
15. Collinge J, Palmer MS, Dryden A. Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease. Lancet 1991;337:1441-1442.
16. Laplanche JL, Delasnerie-Laupretre N, Brandel JP, et al. Molecular genetics of prion diseases in France. Neurology 1994;44:2347-2351.
17. Salvatore M, Genuardi M, Petraroli R, Masullo C, D'Alessandro M, Pocchiari M. Polymorphisms of the prion protein gene in Italian patients with Creutzfeldt-Jakob disease. Hum Genet 1994;94:375-379.
18. Deslys JP, Marce D, Dormont D. Similar genetic susceptibility in iatrogenic and sporadic Creutzfeldt-Jakob disease. Lancet 1995;346:898.
19. Deslys JP, Jaegly A, Huillard d'Aignaux J, et al. Genotype at codon 129 and susceptibility to Creutzfeldt-Jakob disease. Lancet 1998;351:1251.
20. Moore RC, Hope J, McBride PA, et al. Mice with gene targeted prion protein alterations show that Prnp, Sinc and Prni are congruent. Nat Genet 1998;18:126-129.